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Abstract
Purpose The aims of this study were to analyze agreement on
information needs within a group of early-state prostate cancer
patients and to compare information preferences of patients with
the view of health-care professionals about patients’ needs.
Methods Sample consists of patients (n =128) and six sub-
groups of health-care professionals (urologists, n =32; nurses,
n =95; radiotherapy technologists (RTTs), n =36; medical on-
cologists, n =19; radiation oncologists, n =12; general practi-
tioners (GPs), n =10). Information needs have been assessed
with 92 questions concerning prostate cancer and its treatment.
Respondents judged the importance of addressing each ques-
tion. Within- and between-group agreements of patients and
health-care professional groups were estimated with raw agree-
ment indices as well as chance-corrected Kappa and Gwet’s
AC1 measures. Finally, group-specific core items rated with
high importance as well as high agreement were defined.
Results Patients rated on average (median) half, i.e., 51 out 92
items as essential (interquartile range (IQR)=36–66), 26 items
as desired (IQR=14–38), and 10 items as avoidable (IQR=2–
22). Within-group agreement on the presented information
topics is modest for any participating group (AC1patients=
0.319; AC1professionals=0.295–0.398). Agreement between
patients and professionals is low too (AC1=0.282–
0.329). Defining group-specific core sets of information
topics results in 51 items being part of at least one core
set. Concordance of the item core sets of patients and
professionals is moderate with κ =0.38–0.66, sensitivity
of professionals’ core sets for patients’ preferences
varies between 56 and 74 %.
Conclusions Results emphasize the need for dialogue be-
tween doctor/professional and patient in identifying the infor-
mation needed by individual patients and support the impor-
tance of shared decision making.
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Introduction
Patients newly diagnosed with localized prostate cancer are
faced with several treatment options such as watchful waiting
or active surveillance, radical prostatectomy, radiation thera-
py, as well as others. Each treatment has its benefits as well as
its risks and harms. However, scientific evidence on the effi-
cacy of these treatments is still limited, in particular, long-term
randomized clinical trial data are lacking [1, 2]. Thus, to
decide on a specific therapy is a complex undertaking for
patients by having to consider a variety of often sophisticated
data.
Some prostate cancer patients want to know as much as
possible about their disease and its treatment [3–5] but are
overwhelmed by the complexity of information presented at
the same time [6–8]. Therefore, patients are strongly in need
of advice by the physician, and most patients wish to be
involved actively in the treatment decision process. It is there-
fore not surprising that satisfaction with information received
on illness and therapy is positively correlated with quality of
life of prostate cancer patients after treatment [3, 9].
However, patients often report that their information needs
were not satisfactorily met [10–12]. There seems to be also
much heterogeneity with regard to amount and quality of
information delivered by professionals [6, 11]. A majority of
studies are limited to the counseling of patients by urologists,
whereas the specific role of other health professionals is
neglected. However, the literature on multidisciplinary cancer
care underlines the benefit for patients cared of by a multidis-
ciplinary team of specialists [13–15]. In particular, some re-
search proves that the use of specialist nurses in prostate
cancer care results in better covering of patients’ information
needs [16]. Besides, research suggests that the patients’ deci-
sion making on a specific therapy option is highly dependent
on the professional background of the consulting health spe-
cialist [17–19]. To summarize, information needs of prostate
cancer patients are broad and manifold, and health profes-
sionals counsel patients quite inconsistently as well. There-
fore, the present study addresses two main complexes of
questions:
1. Agreement within and between groups of patients and
health professionals, i.e.: To what extent do patients agree
among themselves on specific information topics they
want to be addressed in relation to prostate cancer and
its treatment? And to what extent do health professionals,
being involved in the treatment and care of prostate cancer
patients, agree on information to be delivered to patients?
Finally, do professionals’ ratings of information topics
correspond to patients’ needs?
2. Patients’ and professionals’ core sets of vital information
topics: Is it possible to derive core sets of information
topics on prostate cancer being essential from the view of
patients as well as professionals? To what degree do
patients’ and professionals’ core sets overlap?
Methods
Design
The present study comprises two groups of participants, pa-
tients with established diagnosis of localized prostate cancer
and health professionals engaged in the treatment of these
patients. Both groups were provided with the same question-
naire developed by a Canadian research group led by
Feldman-Stewart [5] and found to be appropriate for prostate
cancer patients in eight other countries [20]. It consisted of 92
information topics about prostate cancer and its treatment.
Patients had to rate the importance of each item retrospective-
ly with regard to their decision making on choosing a specific
treatment option. Professionals had to rate the information
topics the same way, however, by trying to adopt the patient
view.
Samples
Patient sample The study population encompasses patients
with established diagnosis of prostate cancer fulfilling the
following additional selection criteria:
& Localized tumor stage (T1 or T2, PSA<20 ng/mL,
Gleason score<8),
& Having obtained diagnosis 3 to 24 months before date of
study,
& Being treated in one of four urology departments of clinics
in the German-speaking part of Switzerland.
Of the 330 patients fulfilling the abovementioned criteria
for inclusion, 179 (54 %) answered the questionnaires. Final-
ly, 51 patients had to be excluded from the study sample
because of invalid questionnaires or time of diagnosis dating
back more than 24 months. The final study sample consists of
n =128 patients (mean age=66 years). An analysis of response
rates by age and type of treatment indicates no age-related
differences. However, the response differed by type of treat-
ment with a low rate (36 %) for patients who had received
radiotherapy.
Health professionals sample In order to achieve comparabil-
ity with the study by Capirci et al. [21], the same health-care
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professionals were to be included. Therefore, the study popu-
lation encompasses health professionals involved in treating
prostate cancer patients in the 12 months prior to study date.
Samples of physicians were drawn from the registry of the
Swiss Medical Association (FMH) with sample sizes of n =
100 per group (exception: radiation oncologists, n =47).
Nurses and radiotherapy technologists (RTTs) were recruited
from the participating centers with n =197 nurses and n =45
RTTs contacted. The final professional sample that could be
used for analysis consisted of the following: 32 urologists
(response rate=32 %; mean age=47 years; proportion men=
100%), 19medical oncologists (19 %; 47; 68%), 11 radiation
oncologists (23 %; 47; 75 %), 36 RTTs (73 %; 35; 14 %), 11
general practitioners (GPs) (11 %; 54; 60 %), and 99 nurses
(50 %, 38; 16 %). Total sample size was n =208 health
professionals.
Instrument
The questionnaire used was developed by Feldman-Stewart
et al. [5] based on interviews with prostate cancer patients,
their family members, and medical experts. It was revised in
further studies and then used internationally. The authors of
the instrument paid attention to cover all possible aspects that
may be relevant for those involved in the therapeutic decision
making. This work resulted in a set of 92 questions referring to
the epidemiology and natural history of prostate cancer, the
effectiveness and side effects of treatments, and the experience
of the professionals. Patients were asked to go back in their
mind to the time of treatment decision and to indicate for each
item and how important it was for their decision making. The
importance of items had to be rated by using four possible
categories: “no opinion,” “avoid,” “desired,” or “essential.”
Health professionals had to judge the same 92 items in the
same way, however, by taking the view of a hypothetical
prostate cancer patient prior to the treatment decision. In order
to ensure that each participant refers to the same situation, he/
her was provided with a vignette of a hypothetical prostate
cancer patient. After judging the importance of addressing the
various questions, the participants filled out a form providing
further demographic and professional background information.
Statistical analyses
Two types of concordance were analyzed: (1) concordance of
judgments within a specific group of participants (i.e., within
patients, and within professionals) and (2) concordance of
judgments between groups, e.g., patients and urologists. To
express concordance, we use inter-rater agreement coeffi-
cients. The appropriate measure of inter-rater agreement for
our data structure is Fleiss’ Kappa (κ ) coefficient [22], an
extension of the κ measure of Cohen [23]. However, κ
statistics can be inadequately biased by the variation of the
trait prevalence rate and by the magnitude of raters’ classifi-
cation probabilities [24]. Gwet [25] proposed an alternative
agreement measure, the AC1 for categorical data. We will
report both measures, the unweighted Fleiss’-κ as well as
the unweighted AC1 for multiple raters and multiple subjects.
Usually, agreement coefficients measure concordance of
two or more raters’ judgments on one or more subjects. How-
ever, we are also interested in measuring the agreement be-
tween groups of raters, in particular, agreement of patients and
professionals. Technically speaking, we need to analyze the
judgments on multiple subjects of all possible pairs of one rater
group with another rater group.We derived the between-group
agreement measure according to the following equation:
C12 ¼ C1þ2− C1
 w1ð Þ þ C2  w2ð Þð Þ
w12
with:
& C1×2=between-group agreement coefficient of group 1
ratings paired with group 2 ratings
& C1+2=total agreement coefficient of pooled group 1 and
group2 ratings
& C1, C2=within-group agreement coefficients of group 1
and group 2
& w1, w2, w1×2=weights for group 1 and 2 as well as for the
combination of both groups.
The calculation of group weights is presented in the
Appendix of this paper. Statistical analyses as well as the
calculation of Fleiss’ Kappa were done with STATA SE 11.
AC1 coefficients were calculated by using AgreeStat, an
EXCELVBA program developed and distributed by Gwet.1
Results
Distribution of item ratings
Figure 1 illustrates that patients rated on average (median)
around half, i.e., 51 out 92 items, as essential (interquartile
range (IQR)=36–66), 26 items as desired (IQR=14–38), and
10 items as avoidable or not assessable (IQR=2–22). The
variation of patient responses is large. This pattern of large
within-group variance holds mostly true for professionals too
with the exception of urologists’ ratings being somewhat more
consistent compared to other groups.
In general, the variation of responses to each judgment
category is much larger within groups than between groups
of participants: one-way ANOVA of category-specific item
responses by group of subjects provided small intraclass
1 http://agreestat.com/agreestat.html
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correlation such as ρ =0.059 (95 % confidence interval (CI)=
0.000–0.161;F =3.57; p =0.002) for “essential.”Quite similar
results are provided for the remaining response categories such
as “desired” with ρ =0.070 (0.000–0.187; 4.11; 0.001) and
“avoid/no opinion” with ρ =0.016 (0.000–0.012; 1.68; 0.124).
Within- and between-group agreement on importance
of judgments
Due to small sample size, we merged medical and radiation
oncologists to one group and excluded GPs from the follow-
ing analyses. First, we calculated for each group of partici-
pants, their raw agreement as well as chance-corrected agree-
ment of ratings using Fleiss’ Kappa (κ ) and Gwet’s AC1.
With regard to overall raw agreement, results (Table 1) indi-
cate that participants within a specific group agree on their
ratings by around half of the total item set. Inspecting
category-specific ratings reveals substantial raw agreement
on the item categories “essential” and “desired,” whereas
agreement on the categories “avoid” and “no opinion” is
weak. However, by correcting for chance agreement,
coefficients become small to moderate depending on type of
measure. Finally, the 95 % CIs indicate that groups do not
differ significantly from each other with regard to the amount
of within-group agreement.
Second, we calculated between-group agreement (cf.
“Methods” and Appendix). Agreement between patients and
professionals varies between κ =0.067–0.096 and AC1=
0.282–0.329 and is comparably small like within-group agree-
ment. The same holds true for agreement between different
professional groups varying from κ =0.085–0.109 and AC1=
0.287–0.363.
Agreement between patients’ and health professionals’ item
core sets
We tried to build core sets of significant items for each study
group (i.e., patients, health professionals). We defined
“significant” as follows:
& an item is rated with high importance (≥67th percentile of
the distribution of item means) and
Fig. 1 Boxplots of number of items judged as “essential”, “desired,” or “avoid”/“no opinion” by patients and health professionals (maximum number of
items=92)
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& high agreement (≥67th percentile of the distribution of
item specific raw agreement) within a sample.
These two rules produce group-specific core sets. The
accordance between the patients’ core set of important items
and a professionals’ core set can then be calculated. Further-
more, the sensitivity (as well as specificity) of professionals’
core set with regard to patients’ core set can be estimated.
Sensitivity is interpreted as a measure of how well the judg-
ments of a specific professional group fit the “important”
information needs of patients.
Table 2 displays the 27 items of the patients’ core set as
well as sensitivity and specificity of the professional sets with
regard to patients’ set. Overall, somewhat more than half (51)
of the items belong to at least one core set. In particular, eight
items of the patients’ core set are part of every professional
core set too (e.g., “What is prostate cancer?”) and another 14
items are part of a majority of professional sets (e.g., “If the
prostate cancer is not treated, will it affect my bladder function-
ing?”). Finally, five items belong to the patients’ core set but
only to a minority or even none of the professionals’ sets (e.g.,
“If the prostate cancer is not treated, how long will I live?”).
Table 3 shows another 21 items being part of at least one
professional but not of the patients’ core set. Only a few items
are part of most professionals’ but not of the patient’s set. A
larger number of 10 items belong only to one professional set.
The concordance of the item sets of patients and profes-
sionals is moderate with κ =0.38–0.66. The sensitivity of
professionals’ core sets varies between 56 and 74 %. Speci-
ficity of professionals’ judgments is higher (80–89 %).
Discussion
Patients newly diagnosed with localized prostate cancer are
faced with several treatment options. To decide on a specific
therapy is a complex undertaking for patients by having to
consider a variety of sophisticated data. The present study
explored the correspondence of professionals’ information
priorities with patients’ information needs. We adapted the
design and instrument of studies by Feldman-Stewart et al. [5]
to a Swiss sample of patients and health professionals. Patients
were presented with 92 information topics on prostate cancer
and its treatment in order to rate the relevance of these topics
with regard to their decision for treatment. Six groups of
health professionals involved in the treatment and care of
prostate cancer patients were presented with the same items,
professionals had to rate the items from the viewpoint of a
hypothetical vignette patient. Results are in line with the
findings of previous studies [3, 4, 10–12], in particular, of
studies by Feldman-Stewart et al. [5, 20], but our study also
reveals some further insights.
Table 1 Within- and between-groups agreement of patients and health professionals about information topics on prostate cancer and its treatment
Chance-corrected agreement Raw agreement
Kappa (95 % CI) AC1 (95 % CI) Overall _1 _2 _3 _4
Within groups
Patients 0.085 (0.067–0.104) 0.319 (0.277–0.361) 0.454 0.040 0.200 0.323 0.607
Nurses 0.103 (0.080–0.126) 0.349 (0.303–0.394) 0.476 0.061 0.170 0.359 0.622
Urologists 0.146 (0.117–0.175) 0.295 (0.251–0.338) 0.447 0.103 0.266 0.408 0.576
RTT 0.090 (0.067–0.112) 0.398 (0.349–0.447) 0.507 0.071 0.105 0.320 0.666
Oncologists 0.096 (0.064–0.127) 0.308 (0.281–0.336) 0.449 0.049 0.196 0.460 0.520
Between pairs of groups
Patient–Nurses 0.077 (0.057–0.096) 0.285 (0.242–0.328)
Patient–Urologists 0.096 (0.076–0.116) 0.282 (0.242–0.322)
Patient–RTT 0.067 (0.050–0.083) 0.329 (0.287–0.372)
Patient–Oncologists 0.077 (0.058–0.096) 0.294 (0.264–0.324)
Nurses–Urologists 0.099 (0.081–0.117) 0.288 (0.249–0.326)
Nurses–RTT 0.087 (0.069–0.105) 0.363 (0.321–0.404)
Nurses–Oncologists 0.086 (0.066–0.105) 0.301 (0.273–0.329)
Urologists–RTT 0.091 (0.075–0.108) 0.292 (0.248–0.336)
Urologists–Oncologists 0.109 (0.089–0.128) 0.287 (0.258–0.315)
RTT–Oncologists 0.085 (0.069–0.102) 0.311 (0.281–0.340)
Answer categories: _1=“avoid,” _2=“no opinion,” _3=“desired,” _4=“essential”
Kappa unweighted Fleiss’ Kappa, AC1 unweighted Gwet’s AC1 for multiple raters and multiple subjects
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First, information needs of patients with localized prostate
cancer are very heterogeneous: whereas some patients are
interested in as much information as possible, others report
quite limited information needs [5, 26–28]. In addition to the
findings of previous research, we have quantified the low
agreement among patients in their appraisal of information
topics. The low agreement suggests that meeting the highly
individual needs of a patient might be a challenging task for
the consulting health professional.
Second, the heterogeneity of patients’ information needs,
however, is mirrored by the information priorities of health
professionals. Results of the few studies investigating the role
of different health specialists in prostate cancer care [17–19]
indicate that how professionals counsel patients as well as
what kind of treatment option they favor is highly dependent
on their professional background. Our study presents findings
for six groups of specialists indicating that, no matter what
specific professional background, health professionals do only
weakly agree among each other on information topics of
importance for patients. We did not corroborate the findings
of Capirci et al. [21] indicating that the central tendencies of
appraisals by professionals are more consistent among each
other than with the central tendencies of the patients’ judg-
ments; however, what is consistent with both that study and
with Feldman-Stewart’s study of professionals in Canada [26]
is the wide differences in the judgments within each profession.
Table 2 Patients’ core set of items (28 out of 92) with high importance as well as high agreement in relation to professionals’ core sets
Items xi p i Core sets Number of sets
What is prostate cancer? 1.90 0.85 I–V 5
If the prostate cancer is not treated, will I die from it? 1.75 0.67 I–V 5
How long can I safely take to make up my mind? 1.74 0.63 I–V 5
How long will it take to finish all my treatment? 1.74 0.63 I–V 5
If I choose radiation treatment, will I have large areas of my body radiated? 1.75 0.68 I–V 5
How does the treatment work? 1.81 0.73 I–V 5
When and how will you know if the treatment is working? 1.80 0.71 I–V 5
Will the treatment affect my bladder control? If so, for how long? 1.83 0.77 I–V 5
What does PSA mean? 1.79 0.73 I, III–V 4
If the prostate cancer is not treated, how fast will it spread? 1.77 0.70 I–IV 4
If the prostate cancer is not treated, will it be painful? 1.61 0.52 I–IV 4
If the prostate cancer is not treated, will it affect my sexual functioning? 1.59 0.51 I, II, IV, V 4
What type of monitoring will there be if I choose no treatment? 1.65 0.58 I–IV 4
How long will I have to wait to start treatment? 1.63 0.55 I–IV 4
What kind of follow-up will take place after my treatment? 1.57 0.51 I, III–V 4
Will the treatment affect my sexual functioning? If so, when and for how long? 1.66 0.56 I, II, III, V 4
If the prostate cancer is not treated, what parts of my body could be affected? 1.73 0.64 I–III 3
If the prostate cancer is not treated, will it affect my bladder functioning? 1.73 0.63 I, II, IV 3
If I do not have the treatment now, can I have it when the cancer gets worse? 1.59 0.52 I, III, V 3
What do we do if the cancer comes back? 1.75 0.68 I, II, III 3
If the treatment is not successful, what are my options? 1.79 0.73 I, II, III 3
If I get one type of treatment, can I have any of the other treatments later? 1.62 0.56 I, III, V 3
If more than one treatment is needed, how much time does each treatment take? 1.62 0.53 I, V 2
When and how will you know if I have been cured? 1.74 0.66 I, II 2
If the prostate cancer is not treated, how long will I live? 1.57 0.51 I 1
Is the equipment at the hospital up to date for treating the prostate cancer? 1.59 0.52 I 1
How experienced is my doctor in treating patients with prostate cancer? 1.55 0.52 I 1
Concordance of professionals’ core set with patients’ core set (27 items) Kappa Sensitivity, % Specificity, %
Urologists (28 items) 0.66 (0.43–0.79) 74.1 (53.7–88.9) 87.7 (77.2–94.5)
Nurses (29 items) 0.54 (0.35–0.73) 70.4 (49.8–86.2) 84.6 (73.5–92.4)
RTT (29 items) 0.38 (0.18–0.59) 59.3 (38.8–77.6) 80.0 (68.2–88.9)
Oncologists (22 items) 0.47 (0.27–0.68) 55.6 (35.3–74.5) 89.2 (79.1–95.6)
xi : item mean of patients (−1: “avoid”; 0: “no opinion”; 1: “desired”; 2: “essential”); p i: item-specific raw agreement of patients; core sets: I patients; II
nurses; III: urologists; IV RTT; Voncologists
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Taking into account the modest within-group agreement of
patients as well as of all groups of participating health profes-
sionals, it is not surprising that between-group agreement is
modest too, i.e.: not only do the appraisals of health profes-
sionals correspond only moderately with the patient needs but
also different groups of professionals agree only modestly
with each other on information priorities.
Third, despite the heterogeneity of the information needs of
patients as well as the priorities of professionals, we tried to build
core sets of items vital to at least one group of study participants.
Applying the rule that a specific item has to be rated highly and
with strong consensus results in around half (51 of 92) of the
presented information topics being part of at least one core set of
a specific group. Correspondence between patients’ and profes-
sionals’ ratings of core set information topics is more pro-
nounced compared to the agreement on the entire item pool.
The majority (81 %) of the information topics within the patient
core set are also part of at least three out of five core sets of
professionals. Thus, in addition to the findings of other studies
[21, 26, 29], we can conclude that there are some information
topics on prostate cancer and its therapy with high relevance and
substantial consensus among patients as well as professionals.
Somemethodological limitations of the present study are to
be mentioned: (1) It can be argued that the heterogeneous
appraisals of information topics on prostate cancer is at least in
some part induced by the questionnaire being used. Because it
was designed to reflect a broad range of information needs of
patients [5], high or already substantial agreement on all of the
92 items presented can hardly be expected. (2) The rating
scale of the information topics may not allow for a sufficiently
differentiated appraisal. In fact, the scale does not seem to
display the complete range of possible ratings: subjects were
provided with two categories for positive (“essential,”
“desired”), one category for indifferent (“no opinion”), and
another one for negative (“to avoid”) appraisal. Moreover, the
negative category does not seem to represent the same dimen-
sion with regards to content as the positive categories do.
However, the fact that some participants identified some items
to be “avoided” suggests that adding a negative response
option is an important addition to the more typical assess-
ments of information needs that just elicit ratings from “not
important” to “very important” [4]. (3) The sample of patients
selected for participation might be too heterogeneous with
regard to onset of disease. (4) Patients were asked to rate the
importance of each item retrospectively regarding their deci-
sion making on choosing a specific treatment option. There-
fore, we have to take into account a recall bias, meaning that
memories of what kind of information on treatment that had
been important may differ substantially as a function of the
time since diagnosis. (5) Finally, the previous course of
Table 3 Items belonging to at least one professional core set but not to the patients’ core set
Items xi p i Core sets Number of sets
Will I receive medication for symptom control? 1.46 0.44 II–V 4
If I choose radiation treatment, should I take hormone pills before the radiation? 1.54 0.54 III–V 3
If I delay treatment, is there a chance I can still be cured? 1.55 0.50 III–V 3
Will the treatment cause pain? If so, for how long? 1.55 0.49 II, III, IV 3
What options/treatments do I have if my impotency is permanent? 1.56 0.50 II, III, V 3
If the prostate cancer is not treated, will it disappear on its own? 1.55 0.52 II, IV 2
Where will I go for the treatment? 1.42 0.42 II, IV 2
Can I continue my exercise program during treatment? 1.48 0.45 II, IV 2
Do I continue taking medications (prescribed and over-the-counter) during treatment? 1.54 0.49 II, IV 2
If I delay treatment, will any treatment help me? 1.49 0.48 III, V 2
Could the treatment lead to my death? 1.49 0.50 III, V 2
Are my sons at risk of developing prostate cancer? 1.08 0.32 III 1
If the prostate cancer is not treated, will I still be able to carry on my usual activities? 1.49 0.46 II 1
Will I get the same level of care regardless of my treatment decision? 1.32 0.39 V 1
Can I have sex during the course of treatment? 1.46 0.44 II 1
Will I see my doctor during the treatment? 1.20 0.35 IV 1
Will I lose my gonads/testicles? 1.43 0.44 II 1
Will the treatment make me tired? If so, for how long? 1.23 0.36 IV 1
Will the treatment cause diarrhea? If so, for how long? 1.29 0.37 IV 1
Will the treatment cause bleeding? If so, for how long? 1.45 0.43 IV 1
Will the treatment affect my bowel control? If so, for how long? 1.45 0.44 IV 1
xi : item mean of patients (−1: “avoid”; 0: “no opinion”; 1: “desired”; 2: “essential”); p i: item-specific raw agreement of patients; core sets: I patients; II
nurses; III: urologists; IV RTT; Voncologists
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disease and therapy will influence the appraisal of information
on its nature and treatment options.
Conclusions
Information needs with regard to treatment decision of men
suffering from curable prostate cancer are broad, but very
individual too. Although it is possible to reduce information
about this disease on a core set of topics vital for patients, this
will always result in a substantial number of men with infor-
mation needs not sufficiently covered [30]. Our findings em-
phasize the function of the dialogue between doctor/
professional and patient in providing information on a highly
individual level and support the importance of shared decision
making [7]. Counseling of prostate cancer patients by stan-
dardized guidelines only but also require sensitivity to the
patients’ needs [31].
Furthermore, results suggest that health professionals even
within the same speciality counsel men suffering from pros-
tate cancer quite inconsistently [6, 32]. A good working
exchange between different doctors as well as other profes-
sionals caring for patients seems to be of particular impor-
tance. Case management approaches to the care and coaching
of cancer patients [33] as well as multidisciplinary counseling
could be helpful to reach this goal [13–15]. In addition,
the use of web-based tools in the field of prostate
cancer counseling [32] could offer new ways of indi-
vidually and flexibly tailoring knowledge transfer from
professionals to patients [34].
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Appendix
Calculation of between-group rater agreement based
on within-group rater agreement
C12 ¼ C1þ2− C1
 w1ð Þ þ C2  w2ð Þð Þ
w12
with:
& C1×2=between-group agreement coefficient of group 1
ratings paired with group 2 ratings
& C1+2=total agreement coefficient of pooled group 1 and
group2 ratings
& C1, C2=within-group agreement coefficients of group 1
and group 2
& w1,w2, w1×2=weights for group 1 and 2 as wells as for the
combination of both groups.
w1=weighted number of rating pairs in group 1
w1 ¼
n1  n1 − 1ð Þð Þ
2
na  na − 1ð Þð Þ
2
¼ n1  n1 − 1ð Þð Þ  2
na  na − 1ð Þð Þ  2 ¼
n1  n1 − 1ð Þð Þ
na  na − 1ð Þð Þ
w2=weighted number of rating pairs in group 2
w2 ¼ n2  n2−1ð Þð Þna  na−1ð Þð Þ
w1×2=weighted number of rating pairs of group 1 and
group 2 each
w12 ¼ na− na−1ð Þð Þ− n1− n1−1ð Þð Þ þ n2− n2−1ð Þð Þð Þna− na−1ð Þð Þ
& n1=number of raters in group 1
& n2=number of raters in group 2
& na=total number of raters in group 1 and group 2
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